Cargando…

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum

INTRODUCTION: We evaluated a new Simoa plasma assay for phosphorylated tau (P‐tau) at aa217 enhanced by additional p‐tau sites (p217+tau). METHODS: Plasma p217+tau levels were compared to (18)F‐NAV4694 amyloid beta (Aβ) positron emission tomography (PET) and (18)F‐MK6240 tau PET in 174 cognitively i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doré, Vincent, Doecke, James D., Saad, Ziad S., Triana‐Baltzer, Gallen, Slemmon, Randy, Krishnadas, Natasha, Bourgeat, Pierrick, Huang, Kun, Burnham, Samantha, Fowler, Christopher, Rainey‐Smith, Stephanie R., Bush, Ashley I., Ward, Larry, Robertson, Jo, Martins, Ralph N., Masters, Colin L., Villemagne, Victor L., Fripp, Jurgen, Kolb, Hartmuth C., Rowe, Christopher C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984092/ https://www.ncbi.nlm.nih.gov/pubmed/35415202 http://dx.doi.org/10.1002/dad2.12307

Ejemplares similares

Rates of regional tau accumulation in ageing and across the Alzheimer's disease continuum: an AIBL (18)F-MK6240 PET study
por: Krishnadas, Natasha, et al.
Publicado: (2023)

Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
por: Triana‐Baltzer, Gallen, et al.
Publicado: (2021)

Visually Identified Tau (18)F-MK6240 PET Patterns in Symptomatic Alzheimer’s Disease
por: Krishnadas, Natasha, et al.
Publicado: (2022)

Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid
por: Triana-Baltzer, Gallen, et al.
Publicado: (2020)

Relationship between amyloid and tau levels and its impact on tau spreading
por: Doré, Vincent, et al.
Publicado: (2021)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
por: Groot, Colin, et al.
Publicado: (2022)

Correction: Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
por: Groot, Colin, et al.
Publicado: (2022)

(18)F-MK-6240 tau-PET in genetic frontotemporal dementia
por: Levy, Jake P, et al.
Publicado: (2021)

Optimizing quantification of MK6240 tau PET in unimpaired older adults
por: Harrison, Theresa M., et al.
Publicado: (2023)

CenTauR: Toward a universal scale and masks for standardizing tau imaging studies
por: Villemagne, Victor L., et al.
Publicado: (2023)

Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET
por: Tissot, Cécile, et al.
Publicado: (2022)

Case Report: (18)F-MK6240 Tau Positron Emission Tomography Pattern Resembling Chronic Traumatic Encephalopathy in a Retired Australian Rules Football Player
por: Krishnadas, Natasha, et al.
Publicado: (2020)

Mesial temporal tau in amyloid-β-negative cognitively normal older persons
por: Krishnadas, Natasha, et al.
Publicado: (2022)

Cryo-EM structure of Alzheimer’s disease tau filaments with PET ligand MK-6240
por: Kunach, Peter, et al.
Publicado: (2023)

Plasma p‐tau181/Aβ(1‐42) ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ(1‐42) and future cognitive decline
por: Fowler, Christopher J., et al.
Publicado: (2022)

Development, initial validation, and application of a visual read method for [(18)F]MK‐6240 tau PET
por: Shuping, Joanna L., et al.
Publicado: (2023)

A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
por: Brum, Wagner S., et al.
Publicado: (2023)

The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [(18)F]MK6240 Tau PET in Target Regions
por: Tissot, Cécile, et al.
Publicado: (2023)

Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue
por: Aguero, Cinthya, et al.
Publicado: (2019)

Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer’s disease cases
por: Malarte, Mona-Lisa, et al.
Publicado: (2020)

Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
por: Wennström, Malin, et al.
Publicado: (2022)

Dosimetry and efficacy of a tau PET tracer [(18)F]MK-6240 in Japanese healthy elderly and patients with Alzheimer’s disease
por: Ohnishi, Akihito, et al.
Publicado: (2022)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using [(18)F]MK-6240
por: Kolinger, Guilherme D., et al.
Publicado: (2021)

Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease
por: Vacher, Michael, et al.
Publicado: (2022)

Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease
por: Jonaitis, Erin M, et al.
Publicado: (2023)

Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brains
por: Malarte, Mona-Lisa, et al.
Publicado: (2022)

Untangling tau imaging
por: Villemagne, Victor L., et al.
Publicado: (2016)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Bayoumy, Sherif, et al.
Publicado: (2021)

CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
por: Simrén, Joel, et al.
Publicado: (2022)

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2022)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Profiling classical neuropsychiatric biomarkers across biological fluids and following continuous lumbar puncture: A guide to sample type and time
por: Triana-Baltzer, Gallen, et al.
Publicado: (2022)

In vivo quantification of neurofibrillary tangles with [(18)F]MK-6240
por: Pascoal, Tharick A., et al.
Publicado: (2018)

Plasma Glial Fibrillary Acidic Protein Is Associated with (18)F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer’s Disease
por: Chatterjee, Pratishtha, et al.
Publicado: (2023)

Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET
por: Therriault, Joseph, et al.
Publicado: (2023)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
por: Lantero-Rodriguez, Juan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hff1uqvc6cl3fb2ja6q3t0hus8